PrEP Assistance Program Act
Summary
HR7385 is an early-stage bill authorizing up to $10M per grant for PrEP programs, with no specified total funding or direct corporate beneficiaries. It has been referred to committee with 14 cosponsors, all Democrats. At this procedural stage, the bill has no measurable market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7385 is an early-stage authorization bill with zero appropriated funding
- 2.All 14 cosponsors are Democrats—low passage probability in Republican-controlled House
- 3.No direct corporate beneficiaries; the funding mechanism is grants to eligible entities, not contracts to drug manufacturers
Market Implications
No market implications at this stage. The bill is purely procedural. If it advanced to a committee markup with a specified funding amount ($500M+), Gilead Sciences ($GILD) would be the primary beneficiary as the dominant PrEP manufacturer. But that scenario requires the bill to pass a Republican House and be signed into law—a low-probability event. No action required for retail investors.
Full Analysis
HR7385, the PrEP Assistance Program Act, was introduced on February 4, 2026, and referred to the House Committee on Energy and Commerce. The bill authorizes the CDC and HRSA to establish a grant program for pre-exposure prophylaxis (PrEP) for HIV prevention, with grants capped at $10 million per eligible entity. No total appropriation is specified; this is an authorization-only bill. Actual funding would require a separate appropriations bill.
The bill has 14 cosponsors, all Democrats, and no Republican cosponsors. The sponsor, Rep. Watson Coleman (D-NJ), is a junior member without committee leadership. The bill is in the earliest legislative stage—no hearings, no markup, no CBO score. Passage probability in the Republican-controlled House is extremely low.
No executive actions are relevant to this bill. The DPA memoranda on energy infrastructure (Apr 20, 2026) have no connection to HIV prevention grant programs.
There are no publicly traded companies that derive material revenue from PrEP grant programs. PrEP drugs (Truvada, Descovy, Apretude) are manufactured by Gilead Sciences ($GILD) and ViiV Healthcare (GSK, $GSK), but this grant program does not mandate purchasing, name drug manufacturers, or allocate specific funding. The mechanism is grants to community organizations and health departments—not direct contracts to pharmaceutical companies. The $10M per-grant cap is too small to move stock prices for any public company.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
PrEP and PEP are Prevention Act
EPIC Act of 2025
End the Vaccine Carveout Act
Maternal Vaccination Act
Elijah E. Cummings Family Asthma Act
Protecting Americans from Unsafe Drugs Act of 2026
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →